Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
Related Experiment Video
Updated: Dec 8, 2025
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China; Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province, Liaoning, China.
Abstract:
Defective DNA repair is one of the most important features of tumors. BRCA1/2 participates in homologous recombination repair as a key tumor suppressor gene. BRCA1/2 mutation is an important biomarker for predicting the sensitivity of platinum salts and Poly (ADP-ribose) polymerase (PARP) inhibitors in breast cancer, ovarian cancer, and other cancers. However, epigenetic modifications and other mutations in homologous recombination repair (HRR) genes can also cause homologous recombination deficiency (HRD). Patients with no BRCA1/2 mutations, but bearing similar molecular phenotypes (BRCAness) can still obtain clinical benefits from treatment with platinum salts or PARP inhibitors. Therefore, an accurate assessment of HRD is essential for the formulation of personalized treatments. However, methods to identify HRD in tumors vary and are controversial. Currently, genomic scar assays have been used in multiple clinical trials to assess patient clinical benefit. This review summarizes the therapeutic effects of platinum salts and PARP inhibitors in breast and ovarian cancer, clarifies the predictive value of genomic scar assays in evaluating the clinical benefit of different patient groups and treatment options, and proposes the limitations and optimization of current HRD scoring methods. Using and optimizing genomic scar assays can help to accurately screen the population with the most benefit, expand the scope of drug application, and make the most suitable clinical decision based on individual differences.
Insights
Homologous recombination deficiency (HRD) is crucial for cancer treatment. Genomic scar assays can accurately assess HRD, guiding personalized therapy with platinum salts and PARP inhibitors for better patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Defective DNA repair is a hallmark of cancer, with BRCA1/2 mutations impacting homologous recombination repair (HRR).
- BRCA1/2 mutations predict sensitivity to platinum salts and PARP inhibitors in various cancers, including breast and ovarian.
- Homologous recombination deficiency (HRD) can also arise from epigenetic modifications and mutations in other HRR genes, leading to a 'BRCAness' phenotype.
Purpose of the Study:
- To review the therapeutic effects of platinum salts and PARP inhibitors in breast and ovarian cancers.
- To clarify the predictive value of genomic scar assays in assessing clinical benefits for different patient groups and treatments.
- To propose limitations and optimizations for current HRD scoring methods.
Main Methods:
- Review of therapeutic effects and predictive values of genomic scar assays in clinical trials.
- Analysis of current HRD scoring methods, their limitations, and potential optimizations.
Main Results:
- Genomic scar assays are utilized in clinical trials to assess patient benefit.
- Accurate HRD assessment is essential for personalized treatment strategies.
- Optimizing genomic scar assays can expand drug applicability and improve clinical decision-making.
Conclusions:
- Genomic scar assays offer a valuable tool for screening patient populations who will benefit most from platinum salts and PARP inhibitors.
- Further optimization of HRD scoring methods is needed to refine patient selection and treatment strategies.
- Personalized treatment decisions based on accurate HRD assessment can enhance therapeutic efficacy and patient outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


